Hydroxocobalamin G.L. Pharma (Hydroxocobalamin Acetate)

Hydroxocobalamin is converted to active cobalamin co‑factors that support methionine synthase and methylmalonyl‑CoA mutase, essential enzymes for DNA synthesis, red blood cell formation, and neurologic function, while also binding cyanide to form non‑toxic cyanocobalamin.

The prescribed dose and administration schedule are determined by the treating clinician based on the specific indication, patient condition, and clinical guidelines. Dosage should not be altered without medical advice.

Safety data for Hydroxocobalamin in pregnancy and lactation are limited. Its use should be considered only if the potential benefit justifies any potential risk to the fetus or infant, and it must be prescribed by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Hydroxocobalamin differs from cyanocobalamin and methylcobalamin in its longer plasma half‑life and its ability to directly bind cyanide. It is often preferred for treating cyanide poisoning and for patients requiring sustained B12 levels, whereas other forms may be used for routine supplementation.

The product should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use to maintain stability.

Hydroxocobalamin is administered by a healthcare professional via intramuscular or subcutaneous injection, following aseptic technique. The injection site and route are selected based on the clinical indication and patient factors.

Serious adverse reactions include anaphylaxis, severe hypersensitivity, hypotension, hemolysis, Stevens‑Johnson syndrome, and rare thromboembolic events. Immediate medical attention is required if any of these symptoms occur.

Patients with known hypersensitivity to hydroxocobalamin or any component of the formulation should avoid its use. Caution is also advised for individuals with severe renal impairment or those receiving interacting medications without appropriate monitoring.